CA2395305A1 - Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete - Google Patents

Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete Download PDF

Info

Publication number
CA2395305A1
CA2395305A1 CA002395305A CA2395305A CA2395305A1 CA 2395305 A1 CA2395305 A1 CA 2395305A1 CA 002395305 A CA002395305 A CA 002395305A CA 2395305 A CA2395305 A CA 2395305A CA 2395305 A1 CA2395305 A1 CA 2395305A1
Authority
CA
Canada
Prior art keywords
polyamine
spermidine
advantageously
glucose
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002395305A
Other languages
English (en)
French (fr)
Inventor
Nushin Banu Helene Aghajari
Xavier Guy Robert
Richard Michel Haser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2395305A1 publication Critical patent/CA2395305A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002395305A 1999-12-23 2000-12-20 Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete Abandoned CA2395305A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR99/16409 1999-12-23
FR9916409A FR2802817B1 (fr) 1999-12-23 1999-12-23 Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete
PCT/FR2000/003600 WO2001047528A2 (fr) 1999-12-23 2000-12-20 Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete

Publications (1)

Publication Number Publication Date
CA2395305A1 true CA2395305A1 (fr) 2001-07-05

Family

ID=9553772

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002395305A Abandoned CA2395305A1 (fr) 1999-12-23 2000-12-20 Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete

Country Status (7)

Country Link
US (1) US20030143713A1 (enExample)
EP (1) EP1239863A2 (enExample)
JP (1) JP2003518501A (enExample)
AU (1) AU2687301A (enExample)
CA (1) CA2395305A1 (enExample)
FR (1) FR2802817B1 (enExample)
WO (1) WO2001047528A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030013772A1 (en) * 2000-02-23 2003-01-16 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US20050085555A1 (en) * 1997-08-21 2005-04-21 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
WO2000066587A2 (en) * 1999-04-30 2000-11-09 Slil Biomedical Corporation Polyamines and their use in therapy
MXPA01011008A (es) 1999-04-30 2003-06-30 Slil Biomedical Corp Conjugados analogos de poliamina y conjugados de quinona novedosos como terapia para canceres y enfermedades de la prostata.
WO2002091989A2 (en) 2000-11-08 2002-11-21 Slil Biomedical Corporation Antiviral therapies using polyamine or polyamine analog-amino acid conjugates
WO2003033455A1 (en) * 2001-10-16 2003-04-24 Slil Biomedical Corporation Oligoamine compounds and derivatives thereof for cancer therapy
JP2004189714A (ja) * 2002-12-09 2004-07-08 Rasanen Tiina-Liisa すい臓炎の治療と予防ならびに肝臓再生機能の誘導のための薬剤
WO2007035703A1 (en) 2005-09-20 2007-03-29 Schering Corporation 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8153611B2 (en) * 2007-06-28 2012-04-10 Basf Beauty Care Solutions France S.A.S. Use of sulfated oligosaccharides as slimming cosmetic ingredients
FR2917971B1 (fr) * 2007-06-28 2009-10-23 Engelhard Lyon Soc Par Actions Composition amincissante
WO2009000935A1 (en) * 2007-06-28 2008-12-31 Basf Beauty Care Solutions France Sas Slimming composition
CA2703203C (en) 2007-10-22 2015-12-15 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
CA2724426A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
ES2627848T3 (es) 2008-06-04 2017-07-31 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
RU2392933C2 (ru) * 2008-07-18 2010-06-27 Учреждение Российской Академии Медицинских Наук Научно-исследовательский институт экспериментальной медицины Северо-западного отделения РАМН (НИИЭМ СЗО РАМН) Средство, обладающее гиполипидемическими свойствами
EP2318388A2 (en) 2008-07-23 2011-05-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
US8361959B2 (en) 2008-10-03 2013-01-29 Merck Sharp & Dohme Corp. Spiro-imidazolone derivatives as glucagon receptor antagonists
CA2739491A1 (en) 2008-10-16 2010-04-22 Schering Corporation Azine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2010071822A1 (en) 2008-12-19 2010-06-24 Schering Corporation Piperidine and piperazine derivatives and methods of use thereof
WO2010071819A1 (en) 2008-12-19 2010-06-24 Schering Corporation Bicyclic heterocyclic derivatives and methods of use thereof
EP2382204B1 (en) 2008-12-23 2018-07-11 Merck Sharp & Dohme Corp. Pyrimidine derivatives as gpcr modulators for use in the treatment of obesity and diabetes
AU2009330208A1 (en) 2008-12-23 2011-08-04 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
JP2012520887A (ja) 2009-03-18 2012-09-10 シェーリング コーポレイション ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
EP2414348B1 (en) 2009-04-03 2013-11-20 Merck Sharp & Dohme Corp. Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders
EP2440553B1 (en) 2009-06-12 2017-08-23 Merck Sharp & Dohme Corp. Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
EP2477498A4 (en) 2009-09-14 2013-02-27 Merck Sharp & Dohme INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE
EP2485735B1 (en) 2009-10-08 2015-07-29 Merck Sharp & Dohme Corp. Inhibitors of fatty acid binding protein (fabp)
CA2778684A1 (en) 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
US8912206B2 (en) 2009-11-23 2014-12-16 Merck Sharp & Dohme Corp. Pyrimidine ether derivatives and methods of use thereof
WO2011062885A1 (en) 2009-11-23 2011-05-26 Schering Corporation Fused bicyclic pyrimidine derivatives and methods of use thereof
US9301929B2 (en) 2009-11-24 2016-04-05 Merck Sharp & Dohme Corp. Substituted biaryl derivatives and methods of use thereof
WO2011113060A2 (en) * 2010-03-12 2011-09-15 Trana Discovery, Inc. Antiviral compounds and methods of use thereof
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
ITMI20130555A1 (it) * 2013-04-09 2014-10-10 Giuliani Spa Composizione farmaceutica o cosmetica per contrastare l¿invecchiamento della pelle attraverso un¿azione antiinfiammatoria
PL3004138T3 (pl) 2013-06-05 2024-07-29 Bausch Health Ireland Limited Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1768934A1 (de) * 1968-07-15 1972-03-16 Bayer Ag Verfahren zur Anreicherung von Polypeptiden,vorzugsweise von Enzymen und Enzym-Inhibitoren
US4228274A (en) * 1976-09-28 1980-10-14 Merck & Co., Inc. 1-Substituted glycopyranosides
DE3123520A1 (de) * 1981-06-13 1982-12-30 Bayer Ag, 5090 Leverkusen Gesaettigte aminocyclitderivate, ihre herstellung undsie enthaltende arzneimittel
US5141739A (en) * 1986-07-03 1992-08-25 Advanced Magnetics, Inc. Delivery of x-ray contrast agents using receptor mediated endocytosis
JPH03502796A (ja) * 1988-02-19 1991-06-27 ジ・アップジョン・カンパニー 高コレステロール血症の治療に有用な親脂性ポリアミン類
ATE83658T1 (de) * 1988-11-25 1993-01-15 Lubec Gert Behandlung von durch glucose ausgeloester quervernetzung von collagen bei diabetes mellitus-patienten durch arginin, spermidin, kreatin oder agmatin.
US5077313A (en) * 1988-11-25 1991-12-31 Gert Lubec Process for inhibiting pathological collagen cross-linking in diabetes patients
DD298412A5 (de) * 1989-04-28 1992-02-20 ������@���Kk�� Verfahren zur herstellung von polypeptiden, die geeignet sind als antagonisten exzitatorischer aminosaeure-neurotransmitter und/oder blocker der calciumkanaele
AU5739494A (en) * 1992-12-03 1994-06-22 Aristidis S. Charonis Protective role of polyamines in modifications of basement membrane macromolecules
US5744453A (en) * 1996-01-05 1998-04-28 Mintz; Clifford S. Polyamine conjugates for treatment of infection
NL1004379C2 (nl) * 1996-10-29 1998-05-08 Borculo Cooep Weiprod Toepassing van suikeraminen en suikeramiden als lijm, alsmede nieuwe suikeraminen en suikeramiden.
US7087648B1 (en) * 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs

Also Published As

Publication number Publication date
FR2802817A1 (fr) 2001-06-29
WO2001047528A2 (fr) 2001-07-05
AU2687301A (en) 2001-07-09
WO2001047528A3 (fr) 2002-06-20
JP2003518501A (ja) 2003-06-10
EP1239863A2 (fr) 2002-09-18
FR2802817B1 (fr) 2002-10-11
US20030143713A1 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
WO2001047528A2 (fr) Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete
Carta et al. Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule
Ilies et al. Binding of α, α-disubstituted amino acids to arginase suggests new avenues for inhibitor design
JPH07503713A (ja) 蛋白質の高度グリコシル化阻害剤として有用なアミノ酸
LU84157A1 (fr) Nouvelles 1,2-diaminocyclobutene-3,4-diones,leur procede de preparation et composition pharmaceutique les contenant
CN103228668A (zh) 抗糖尿病的苯基丙酮酸烯醇糖苷
CA2387591A1 (fr) Utilisation de derives d'indirubine pour la fabrication de medicaments
Nahrjou et al. Targeting of GLUT5 for transporter-mediated drug-delivery is contingent upon substrate hydrophilicity
JPH11513381A (ja) システインプロテアーゼ阻害剤としての金属錯体
CN117720598A (zh) 一种肉桂酸衍生物及其制备方法与应用
WO2005039589A2 (fr) Modulateurs des canaux cftr
CN109912688B (zh) 一类ptp1b多肽抑制剂及其制备方法和应用
Narayanaswamy et al. Synthesis, characterization, and hypoglycemic efficacy of nitro and amino acridines and 4-phenylquinoline on starch hydrolyzing compounds: an in silico and in vitro study
CA2215476C (fr) Analogues de l'arginine ayant une activite en tant qu'inhibiteurs de la no synthase
CN118234743A (zh) 含订合钉的多肽及其应用
CN120818044B (zh) 牦牛皮低聚肽及其制备方法和应用、功能性食品或药品
BRPI0804764A2 (pt) inibidores da alfa-glicosidades, composições farmacêuticas compreendendo os mesmos e processo para sua preparação
FR2721612A1 (fr) Nouveaux dérivés d'oligosides, leur procédé de préparation et leurs applications.
CN120484056B (zh) 一种α-葡萄糖苷酶抑制肽及其应用
US11608353B2 (en) Amylase inhibitor compounds, methods of their use and compositions thereof
Karim et al. Targeting Peroxisomal Transport in Trypanosoma.
US7320998B1 (en) Carbohydrate analog inhibitors of alpha-amylase
CN121005658A (zh) 一种化合物k802及其在制备糖尿病药物中的应用
CN121005685A (zh) 一种化合物k413及其在制备糖尿病药物中的应用
WO2003066647A2 (fr) Synthese de molecules de type inositolphosphate glycanne: traitement des troubles de la proliferation cellulaire et de desordres metaboliques caracterises par une resistance a l'insuline

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead